Highlights
KLSE: DPHARMA (7148)       DUOPHARMA BIOTECH BHD MAIN : Health Care
Last Price Today's Change   Day's Range   Trading Volume
1.21   +0.01 (0.83%)  1.19 - 1.24  2,090,600
Analyze this stock with MQ Trader system

Financials


Market Cap: 801 Million

Market Cap 801 Million
NOSH 662 Million

Latest Audited Result:  30-Apr-2018

Latest Audited Result: 30-Apr-2018
Announcement Date 30-Apr-2018
Next Audited Result: 30-Apr-2019
Est. Ann. Date: 30-Apr-2019
Est. Ann. Due Date: 27-Oct-2019

Latest Quarter:  31-Dec-2018 [#4]

Latest Quarter: 31-Dec-2018 [#4]
Announcement Date 18-Feb-2019
Next Quarter: 31-Mar-2019
Est. Ann. Date: 28-May-2019
Est. Ann. Due Date: 30-May-2019
QoQ | YoY   16.95%  |    21.05%

Annual (Unaudited) ( EPS: 7.26, P/E: 16.82 )

Revenue | NP to SH 498,722  |  47,641
RPS | P/RPS 75.35 Cent  |  1.61
EPS | P/E | EY 7.26 Cent  |  16.82  |  5.95%
DPS | DY | Payout % 5.50 Cent  |  4.55%  |  76.41%
NAPS | P/NAPS 0.73  |  1.66
YoY   12.12%
NP Margin | ROE 9.55%  |  9.86%
F.Y. | Ann. Date 31-Dec-2018  |  18-Feb-2019

T4Q Result ( EPS: 7.22, P/E: 16.77 )

Revenue | NP to SH 498,722  |  47,776
RPS | P/RPS 75.35 Cent  |  1.61
EPS | P/E | EY 7.22 Cent  |  16.77  |  5.96%
DPS | DY | Payout % 4.63 Cent  |  3.83%  |  64.21%
NAPS | P/NAPS 0.73  |  1.66
QoQ | YoY   5.52%  |    12.44%
NP Margin | ROE 9.55%  |  9.89%
F.Y. | Ann. Date 31-Dec-2018  |  18-Feb-2019

Annualized Result ( EPS: 7.26, P/E: 16.82 )

Revenue | NP to SH 498,722  |  47,641
RPS | P/RPS 75.35 Cent  |  1.61
EPS | P/E | EY 7.26 Cent  |  16.82  |  5.95%
DPS | DY | Payout % -
NAPS | P/NAPS -
QoQ | YoY   7.39%  |    12.12%
NP Margin | ROE 9.55%  |  9.86%
F.Y. | Ann. Date 31-Dec-2018  |  18-Feb-2019


Hints :
Click the QoQ or YoY on table to view the QoQ or YoY Financial Result page.

Click here to modify the Visible Columns.

Date Financial Result Financial Ratio Per Share Item Performance Valuation (End of Quarter) Valuation (Ann. Date)
F.Y. Ann. Date Quarter # Revenue PBT NP NP to SH Div Net Worth Div Payout % NP Margin ROE NOSH RPS Adj. RPS EPS Adj. EPS DPS Adj. DPS NAPS Adj. NAPS QoQ YoY EOQ Date EOQ Price EOQ P/RPS EOQ P/EPS EOQ P/NAPS EOQ EY EOQ DY ANN Date ANN Price ANN P/RPS ANN P/EPS ANN P/NAPS ANN EY ANN DY
31-Dec-2018 18-Feb-2019 31-Dec-2018 4 115,634 17,658 14,369 14,369 26,475 483,173 184.25% 12.43% 2.97% 661,881 17.47 17.47 2.17 2.17 4.00 4.00 0.7300 0.73   16.95%   21.05% 31-Dec-2018 0.95 5.44 43.76 1.30 2.29% 4.21% 18-Feb-2019 1.03 5.90 47.45 1.41 2.11% 3.88%
31-Dec-2018 28-Nov-2018 30-Sep-2018 3 125,838 15,838 12,286 12,286 - 501,487 - % 9.76% 2.45% 659,852 19.07 19.01 1.86 1.86 0.00 0.00 0.7600 0.76   18.83%   7.72% 28-Sep-2018 1.23 6.45 66.06 1.62 1.51% 0.00% 28-Nov-2018 1.07 5.61 57.47 1.41 1.74% 0.00%
31-Dec-2018 26-Nov-2018 30-Jun-2018 2 123,991 12,915 10,339 10,339 4,199 209,983 40.62% 8.34% 4.92% 279,978 44.29 18.73 1.59 1.56 1.50 0.63 0.7500 0.32   -4.11%   7.11% 29-Jun-2018 1.30 2.94 35.20 1.73 2.84% 1.15% 26-Nov-2018 1.08 2.44 29.25 1.44 3.42% 1.39%
31-Dec-2018 28-May-2018 31-Mar-2018 1 133,259 13,255 10,647 10,782 - 206,429 - % 7.99% 5.22% 278,959 47.77 20.13 3.82 1.63 0.00 0.00 0.7400 0.31   -9.17%   25.11% 30-Mar-2018 2.80 5.86 72.44 3.78 1.38% 0.00% 28-May-2018 3.35 7.01 86.67 4.53 1.15% 0.00%
31-Dec-2017 28-Feb-2018 31-Dec-2017 4 112,253 12,825 11,768 11,870 16,737 479,809 141.01% 10.48% 2.47% 278,959 40.24 16.96 4.22 1.79 6.00 2.53 1.7200 0.72   4.08%   40.84% 29-Dec-2017 2.53 6.29 59.46 1.47 1.68% 2.37% 28-Feb-2018 2.97 7.38 69.80 1.73 1.43% 2.02%
31-Dec-2017 17-Nov-2017 30-Sep-2017 3 115,379 14,207 11,127 11,405 - 474,230 - % 9.64% 2.40% 278,959 41.36 17.43 3.99 1.72 0.00 0.00 1.7000 0.72   18.15%   79.86% 29-Sep-2017 2.20 5.32 53.81 1.29 1.86% 0.00% 17-Nov-2017 2.20 5.32 53.81 1.29 1.86% 0.00%
31-Dec-2017 25-Aug-2017 30-Jun-2017 2 117,049 12,642 9,641 9,653 6,973 463,071 72.25% 8.24% 2.08% 278,959 41.96 17.68 3.46 1.46 2.50 1.05 1.6600 0.70   12.01%   114.37% 30-Jun-2017 2.25 5.36 65.02 1.36 1.54% 1.11% 25-Aug-2017 2.03 4.84 58.66 1.22 1.70% 1.23%
31-Dec-2017 22-May-2017 31-Mar-2017 1 120,994 11,176 8,618 8,618 - 463,071 - % 7.12% 1.86% 278,959 43.37 18.28 3.43 1.30 0.00 0.00 1.6600 0.70   2.25%   9.88% 31-Mar-2017 2.31 5.33 74.77 1.39 1.34% 0.00% 22-May-2017 2.32 5.35 75.10 1.40 1.33% 0.00%
31-Dec-2016 24-Feb-2017 31-Dec-2016 4 74,033 6,299 8,831 8,428 11,158 454,703 132.40% 11.93% 1.85% 278,959 26.54 11.19 3.41 1.27 4.00 1.69 1.6300 0.69   32.91%   -45.04% 30-Dec-2016 1.98 7.46 65.54 1.21 1.53% 2.02% 24-Feb-2017 2.23 8.40 73.81 1.37 1.35% 1.79%
31-Dec-2016 21-Nov-2016 30-Sep-2016 3 80,302 7,516 6,226 6,341 - 451,913 - % 7.75% 1.40% 278,959 28.79 12.13 2.23 0.96 0.00 0.00 1.6200 0.68   40.82%   -26.46% 30-Sep-2016 2.06 7.16 90.63 1.27 1.10% 0.00% 21-Nov-2016 2.10 7.30 92.39 1.30 1.08% 0.00%
31-Dec-2016 22-Aug-2016 30-Jun-2016 2 79,135 7,723 3,941 4,503 6,973 446,334 154.87% 4.98% 1.01% 278,959 28.37 11.96 1.41 0.68 2.50 1.05 1.6000 0.67   -42.59%   -23.00% 30-Jun-2016 2.04 7.19 126.38 1.28 0.79% 1.23% 22-Aug-2016 2.14 7.54 132.57 1.34 0.75% 1.17%
31-Dec-2016 18-May-2016 31-Mar-2016 1 79,470 9,941 7,828 7,843 - 457,492 - % 9.85% 1.71% 278,959 28.49 12.01 2.81 1.18 0.00 0.00 1.6400 0.69   -48.86%   -12.55% 31-Mar-2016 2.55 8.95 90.70 1.55 1.10% 0.00% 18-May-2016 2.40 8.42 85.36 1.46 1.17% 0.00%
31-Dec-2015 23-Feb-2016 31-Dec-2015 4 89,401 17,529 17,529 15,335 9,172 270,177 59.82% 19.61% 5.68% 166,776 53.61 13.51 9.19 2.32 5.50 1.39 1.6200 0.41   77.84%   37.92% 31-Dec-2015 2.62 4.89 28.49 1.62 3.51% 2.10% 23-Feb-2016 2.61 4.87 28.39 1.61 3.52% 2.11%
31-Dec-2015 24-Nov-2015 30-Sep-2015 3 79,372 11,621 8,623 8,623 - 268,509 - % 10.86% 3.21% 166,776 47.59 11.99 5.17 1.30 0.00 0.00 1.6100 0.41   47.45%   -0.68% 30-Sep-2015 2.72 5.72 52.61 1.69 1.90% 0.00% 24-Nov-2015 2.70 5.67 52.22 1.68 1.91% 0.00%
31-Dec-2015 25-Aug-2015 30-Jun-2015 2 56,308 8,407 5,848 5,848 5,582 189,815 95.47% 10.39% 3.08% 139,570 40.34 8.51 4.19 0.88 4.00 0.84 1.3600 0.29   -34.80%   -22.16% 30-Jun-2015 2.65 6.57 63.25 1.95 1.58% 1.51% 25-Aug-2015 2.40 5.95 57.28 1.76 1.75% 1.67%
31-Dec-2015 18-May-2015 31-Mar-2015 1 45,599 12,198 8,969 8,969 - 205,045 - % 19.67% 4.37% 139,486 32.69 6.89 6.43 1.36 0.00 0.00 1.4700 0.31   -19.34%   7.22% 31-Mar-2015 3.88 11.87 60.34 2.64 1.66% 0.00% 18-May-2015 3.90 11.93 60.65 2.65 1.65% 0.00%
31-Dec-2014 24-Feb-2015 31-Dec-2014 4 51,024 13,921 13,921 11,119 20,128 192,951 181.02% 27.28% 5.76% 138,813 36.76 7.71 8.01 1.68 14.50 3.04 1.3900 0.29   28.07%   19.39% 31-Dec-2014 2.50 6.80 31.21 1.80 3.20% 5.80% 24-Feb-2015 2.92 7.94 36.45 2.10 2.74% 4.97%
31-Dec-2014 21-Nov-2014 30-Sep-2014 3 44,819 11,287 8,682 8,682 - 187,531 - % 19.37% 4.63% 138,912 32.26 6.77 6.25 1.31 0.00 0.00 1.3500 0.28   15.56%   27.94% 30-Sep-2014 3.17 9.83 50.72 2.35 1.97% 0.00% 21-Nov-2014 3.01 9.33 48.16 2.23 2.08% 0.00%
31-Dec-2014 26-Aug-2014 30-Jun-2014 2 40,623 10,107 7,513 7,513 5,554 179,145 73.94% 18.49% 4.19% 138,872 29.25 6.14 5.41 1.14 4.00 0.84 1.2900 0.27   -10.19%   -29.71% 30-Jun-2014 2.97 10.15 54.90 2.30 1.82% 1.35% 26-Aug-2014 3.37 11.52 62.29 2.61 1.61% 1.19%
31-Dec-2014 20-May-2014 31-Mar-2014 1 40,495 11,175 8,365 8,365 - 190,050 - % 20.66% 4.40% 138,723 29.19 6.12 6.03 1.26 0.00 0.00 1.3700 0.29   -10.18%   24.87% 31-Mar-2014 3.03 10.38 50.25 2.21 1.99% 0.00% 20-May-2014 3.09 10.59 51.24 2.26 1.95% 0.00%
31-Dec-2013 26-Feb-2014 31-Dec-2013 4 45,734 9,160 9,313 9,313 18,737 181,818 201.19% 20.36% 5.12% 138,792 32.95 6.91 6.71 1.41 13.50 2.83 1.3100 0.27   37.24%   55.27% 31-Dec-2013 2.58 7.83 38.45 1.97 2.60% 5.23% 26-Feb-2014 2.60 7.89 38.75 1.98 2.58% 5.19%
31-Dec-2013 19-Nov-2013 30-Sep-2013 3 40,845 9,054 6,786 6,786 - 179,017 - % 16.61% 3.79% 138,773 29.43 6.17 4.89 1.03 0.00 0.00 1.2900 0.27   -36.51%   5.34% 30-Sep-2013 2.55 8.66 52.15 1.98 1.92% 0.00% 19-Nov-2013 2.56 8.70 52.35 1.98 1.91% 0.00%
31-Dec-2013 28-Aug-2013 30-Jun-2013 2 37,988 13,007 10,689 10,689 5,552 187,404 51.95% 28.14% 5.70% 138,818 27.37 5.74 7.70 1.61 4.00 0.84 1.3500 0.28   59.56%   55.66% 28-Jun-2013 2.38 8.70 30.91 1.76 3.24% 1.68% 28-Aug-2013 2.44 8.92 31.69 1.81 3.16% 1.64%
31-Dec-2013 27-May-2013 31-Mar-2013 1 37,837 8,956 6,699 6,699 - 176,143 - % 17.70% 3.80% 138,695 27.28 5.72 4.83 1.01 0.00 0.00 1.2700 0.27   11.69%   -0.13% 29-Mar-2013 2.23 8.17 46.17 1.76 2.17% 0.00% 27-May-2013 2.51 9.20 51.97 1.98 1.92% 0.00%
31-Dec-2012 25-Feb-2013 31-Dec-2012 4 35,378 9,000 5,998 5,998 14,576 169,359 243.02% 16.95% 3.54% 138,819 25.48 5.35 4.32 0.91 10.50 2.20 1.2200 0.26   -6.89%   -5.23% 31-Dec-2012 2.13 8.36 49.30 1.75 2.03% 4.93% 25-Feb-2013 2.17 8.51 50.22 1.78 1.99% 4.84%
31-Dec-2012 23-Nov-2012 30-Sep-2012 3 29,521 8,391 6,442 6,442 - 167,991 - % 21.82% 3.83% 138,836 21.26 4.46 4.64 0.97 0.00 0.00 1.2100 0.25   -6.19%   -14.35% 28-Sep-2012 2.36 11.10 50.86 1.95 1.97% 0.00% 23-Nov-2012 2.28 10.72 49.14 1.88 2.04% 0.00%
31-Dec-2012 16-Aug-2012 30-Jun-2012 2 34,355 9,037 6,867 6,867 4,855 162,310 70.71% 19.99% 4.23% 138,727 24.76 5.19 4.95 1.04 3.50 0.73 1.1700 0.25   2.37%   -0.94% 29-Jun-2012 2.23 9.00 45.05 1.91 2.22% 1.57% 16-Aug-2012 2.38 9.61 48.08 2.03 2.08% 1.47%
31-Dec-2012 17-May-2012 31-Mar-2012 1 36,057 8,869 6,708 6,708 - 170,824 - % 18.60% 3.93% 138,881 25.96 5.45 4.83 1.01 0.00 0.00 1.2300 0.26   5.99%   13.23% 30-Mar-2012 2.40 9.24 49.69 1.95 2.01% 0.00% 17-May-2012 2.38 9.17 49.28 1.93 2.03% 0.00%
31-Dec-2011 22-Feb-2012 31-Dec-2011 4 33,036 7,836 6,329 6,329 20,125 163,776 317.98% 19.16% 3.86% 138,793 23.80 4.99 4.56 0.96 14.50 3.04 1.1800 0.25   -15.85%   -26.53% 30-Dec-2011 2.02 8.49 44.30 1.71 2.26% 7.18% 22-Feb-2012 2.12 8.91 46.49 1.80 2.15% 6.84%
31-Dec-2011 21-Nov-2011 30-Sep-2011 3 36,767 9,726 7,521 7,521 - 162,353 - % 20.46% 4.63% 138,763 26.50 5.55 5.42 1.14 0.00 0.00 1.1700 0.25   8.50%   -1.29% 30-Sep-2011 2.10 7.93 38.75 1.79 2.58% 0.00% 21-Nov-2011 2.10 7.93 38.75 1.79 2.58% 0.00%
31-Dec-2011 18-Aug-2011 30-Jun-2011 2 35,345 9,292 6,932 6,932 4,862 154,198 70.14% 19.61% 4.50% 138,917 25.44 5.34 4.99 1.05 3.50 0.73 1.1100 0.23   17.02%   -5.12% 30-Jun-2011 2.34 9.20 46.89 2.11 2.13% 1.50% 18-Aug-2011 2.22 8.73 44.49 2.00 2.25% 1.58%
31-Dec-2011 25-May-2011 31-Mar-2011 1 32,984 7,875 5,924 5,924 - 162,320 - % 17.96% 3.65% 138,735 23.77 4.98 4.27 0.90 0.00 0.00 1.1700 0.25   -31.23%   15.48% 31-Mar-2011 2.35 9.88 55.04 2.01 1.82% 0.00% 25-May-2011 2.57 10.81 60.19 2.20 1.66% 0.00%
31-Dec-2010 23-Feb-2011 31-Dec-2010 4 32,195 8,607 8,614 8,614 152 156,744 1.77% 26.76% 5.50% 138,711 23.21 4.86 6.21 1.30 0.11 0.02 1.1300 0.24   13.06%   9.82% 30-Dec-2010 2.39 10.30 38.49 2.12 2.60% 0.05% 23-Feb-2011 2.45 10.56 39.45 2.17 2.53% 0.04%
31-Dec-2010 26-Nov-2010 30-Sep-2010 3 34,464 10,221 7,619 7,619 - 148,494 - % 22.11% 5.13% 138,779 24.83 5.21 5.49 1.15 0.00 0.00 1.0700 0.22   4.28%   9.96% 30-Sep-2010 2.44 9.83 44.44 2.28 2.25% 0.00% 26-Nov-2010 2.38 9.58 43.35 2.22 2.31% 0.00%
31-Dec-2010 24-Aug-2010 30-Jun-2010 2 35,982 9,790 7,306 7,306 6,250 140,286 85.55% 20.30% 5.21% 138,897 25.91 5.44 5.26 1.10 4.50 0.94 1.0100 0.21   42.42%   -13.87% 30-Jun-2010 2.45 9.46 46.58 2.43 2.15% 1.84% 24-Aug-2010 2.45 9.46 46.58 2.43 2.15% 1.84%
31-Dec-2010 25-May-2010 31-Mar-2010 1 28,796 6,792 5,130 5,130 - 146,967 - % 17.81% 3.49% 138,648 20.77 4.35 3.70 0.78 0.00 0.00 1.0600 0.22   -34.60%   -26.48% 31-Mar-2010 2.40 11.56 64.86 2.26 1.54% 0.00% 25-May-2010 2.38 11.46 64.32 2.25 1.55% 0.00%
31-Dec-2009 23-Feb-2010 31-Dec-2009 4 29,850 8,610 7,844 7,844 16,659 142,996 212.39% 26.28% 5.49% 138,831 21.50 4.51 5.65 1.19 12.00 2.52 1.0300 0.22   13.21%   123.03% 31-Dec-2009 2.40 11.16 42.48 2.33 2.35% 5.00% 23-Feb-2010 2.33 10.84 41.24 2.26 2.42% 5.15%
31-Dec-2009 20-Nov-2009 30-Sep-2009 3 32,188 9,268 6,929 6,929 - 143,023 - % 21.53% 4.84% 138,857 23.18 4.86 4.99 1.05 0.00 0.00 1.0300 0.22   -18.32%   -19.36% 30-Sep-2009 2.58 11.13 51.70 2.50 1.93% 0.00% 20-Nov-2009 2.49 10.74 49.90 2.42 2.00% 0.00%
31-Dec-2009 26-Aug-2009 30-Jun-2009 2 34,062 10,968 8,483 8,483 83 136,061 0.98% 24.90% 6.23% 138,837 24.53 5.15 6.11 1.28 0.06 0.01 0.9800 0.21   21.57%   6.30% 30-Jun-2009 2.13 8.68 34.86 2.17 2.87% 0.03% 26-Aug-2009 2.50 10.19 40.92 2.55 2.44% 0.02%
31-Dec-2009 26-May-2009 31-Mar-2009 1 27,665 9,369 6,978 6,978 - 137,340 - % 25.22% 5.08% 138,727 19.94 4.18 5.03 1.05 0.00 0.00 0.9900 0.21   98.41%   -4.57% 31-Mar-2009 2.10 10.53 41.75 2.12 2.40% 0.00% 26-May-2009 2.34 11.73 46.52 2.36 2.15% 0.00%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.


NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ Δ & YoY Δ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.


Trade this stock with 3 x trading limit. Find out more.
  4 people like this.
 
chandra54 yeah romyzam, will go hopless yet again. forget to smell 1.27. this prise is history
18/09/2018 1:03 PM
chandra54 Post removed. Why?
18/09/2018 1:04 PM
Jordan Khoo Good show ! Very strong... will move tomorrow and profit incoming
18/09/2018 3:26 PM
Gavin Chua may i know CCMBIO's competitors ?
18/09/2018 10:57 PM
jibbie pharmaniaga, yspsah, hovid
19/09/2018 4:38 PM
Romyzam Nice recovery today. More to come tomorrow. Really hope back to 1.27 and above...
19/09/2018 6:28 PM
chandra54 Post removed. Why?
25/09/2018 10:15 AM
Romyzam Cool Chandra. Now accumulation time. I bought total 100k shares from 1.15 to 1.19. If break 1.14 again then cut lo
25/09/2018 11:58 AM
Romyzam Nicely back to 1.26 today.
26/09/2018 1:16 PM
Romyzam Sold back all 1.23 to 1.26. Good luck those still holding. Good counter but too slow. Thanks ccmdbio for the quick bucks.
02/10/2018 7:14 PM
Investeye Take opportunity to accumulate more based on EPF kept accumulating recently. In fact after holding some lots for 1.5 yrs, it is still gaining at this price ( due to bonus 4:3 issuing 15 maths ago)
03/10/2018 8:24 PM
04TSH Interesting feedbacks and advices guys
04/10/2018 4:09 PM
Romyzam Buy back 1.12. Cheap sale.
11/10/2018 12:05 PM
Stephenloo Declared 1.5 cent dividen
22/10/2018 7:29 PM
YKLIEW Bought 1-28 down 20 sen but get 1.5 sen dividend. Terrible investment yo
02/11/2018 9:45 PM
moneytrail Collect for long term, consistent profit this 2 years. Factory expansion to bear fruit 2020. Niche product and stem cells product, hope to give higher margin to offset margin erosion from competitive generic drugs.
03/11/2018 3:46 PM
jinghee Will the government budget benefit this company?
08/11/2018 8:55 PM
Hafid people are selling
15/11/2018 4:16 PM
kmwong8711 Today quarter results out??
16/11/2018 10:55 AM
necro I must said recent acquisition & ventures were uninteresting to investor, too many drug & substances in pipeline. Investor dont understand of what is the drug is going to do with Malaysia market.

Asean is not like Singapore, Japan or Korea where the country spend 7% of GDP for healthcare budget, Malaysia for example is only use of 3% GDP for healthcare budget.

Malaysia healthcare priority budgeting only for "3 serangkai" diseases which diabetes, high blood pressure & heart diseases. Disease like autoimmune, chronic kidney disease(ckd), obstetric &, gynaecology using advance medication were too expensive for government to used.

Hopefully CEO does not to eager to pursuing pipeline quantity but focus more on quality, he must realise that that CCMDBIO is conglomerates not science lab where he can test new drug or substances onto Malaysian people.
22/11/2018 9:55 AM
moneytrail Good resukts
28/11/2018 10:56 PM
Tete7893 Luckily run early.
26/12/2018 5:45 PM
Yi Heng 0.94 all in
22/01/2019 7:22 PM
Nicholasming91 Can buy wow
18/02/2019 7:01 PM
Yi Heng yes, dividend 4 sen if approved
18/02/2019 7:23 PM
Investeye CCM Duopharma Biotech Bhd’s fourth quarter net profit rose 18.45% to RM14.37 million from RM12.13 million a year ago, due to higher revenue and changes in accounting policies arising from adoption of the Malaysian Financial Reporting Standards 9 (MFRS 9).
Earnings per share for the quarter ended Dec 31, 2018 rose to 2.17 sen from 1.86 sen.
Quarterly revenue was up 3.01% to RM115.63 million, from RM112.25 million previously, the group said in a filing with Bursa Malaysia.
CCM Duopharma has declared a final dividend of four sen, bringing total payout for FY18 to 5.5 sen, as against 3.64 sen in FY17.
The group has also proposed that the dividend reinvestment plan would apply to the final dividend.
For FY18 as a whole, CCM Duopharma’s net profit increased 12.19% to RM47.64 million or 7.26 sen per share from RM42.46 million or 6.52 sen per share last year, while revenue grew 6.57% to RM498.72 million from RM467.99 million.
On prospects, the group said it sees opportunities from the increase in allocation for health services to RM29 billion in Budget 2019 including RM10.8 billion to restore clinics and hospitals as well to buy medicine and medical equipment.
“The group will also continue its foray into the specialty products as one of its strategies moving forward to create a pool of niche products,” said CCM Duopharma, adding that it has recently received registration approval for Erysaa, an erythropoeitin product.
Barring any unforeseen circumstances, the group expects to achieve satisfactory results in FY19.
18/02/2019 10:08 PM
shpg22 Liquidity has deteriorated quite rapidly, still able to give 4cents dividend. Good management
18/02/2019 10:49 PM
chshzhd good dividend
19/02/2019 10:41 AM
chshzhd but profit improved is due to adoption of MFRS.
19/02/2019 10:45 AM
Yi Heng wait it correction and buy again :)
19/02/2019 12:30 PM
tac2255 finally it gap up
19/02/2019 4:14 PM
LOLANTO what correction.... it's just the very beginning of the rally. buy before it is too late!
19/02/2019 8:20 PM
James Ng https://klse.i3investor.com/blogs/general/194224.jsp
[转贴] [CCM DUOPHARMA BIOTECH BHD:进军特种产品,作为其创建一系列利基产品的战略之一,它最近获得了红细胞生成素产品Erysaa的注册批准] - James的股票投资James Share Investing
20/02/2019 11:52 AM
Investeye SHAH ALAM (Feb 20): CCM Duopharma Biotech Bhd (CCMD) is hopeful of getting its RM10 million goods and services tax (GST) refund from the government within this year.

"We are in the process [of getting the refund]. There are still questions that need to be addressed with the Ministry of Finance (MoF), but we are quite happy with the announcement about the refund. Hopefully, it will be refunded within this financial year," CCMD group managing director Leonard Ariff Abdul Shatar told the press at its extraordinary general meeting (EGM) here.

Last August, Leonard Ariff told The Edge Financial Daily that the government still owed CCMD about RM10 million in GST refunds.
20/02/2019 5:07 PM
factorrumour "A final dividend of 4.0sen/share was proposed (FY18: 5.5sen/share vs. FY17: 3.6sen/share). This translates to a dividend payout ratio of 68%, which is much higher than FY17 payout ratio of 55%."

how did this guy get FY17: 3.6sen/share?
22/02/2019 10:38 PM
factorrumour congrats to all shareholders, a new beginning awaits you all

duopharma biotech!
25/02/2019 10:51 PM
cmshyong when is the ex date for 4 sen dividen?
26/02/2019 7:35 PM
catchcon factorrumour congrats to all shareholders, a new beginning awaits you all

duopharma biotech!

It's good brother, better things to come.
11/03/2019 5:13 AM
chshzhd @factorrumour div for fy17 was 3.6sen bcos the adjustment of bonus issue at june last year
12/03/2019 11:43 AM
chshzhd ..so div 5.5sen for fy18 actually is an improvement of 55% !
12/03/2019 11:45 AM
chshzhd @cmshyong the ex date for 4 sen will be around june this year.
12/03/2019 11:46 AM
Chengkai Kok 目标价:1.52令吉
最新进展:

联合药业(DPHARMA,7148,主板保健股)持续预见大马公共和私人保健领域需求强劲,归功政府增加卫生部拨款。

联合药业去年的销售量仍是大马领先业者;而以销售值来看,从第三名攀升至第二名。

该公司近期取得相关机构批准,出售红血球生成素(EPO)生物仿制药,同时肿瘤设备料于今年第三季推介。

在大马,肿瘤科产品市值高达4亿令吉,所以该利基产品有巨大的机会。

目前本地还未有肿瘤科的设备,该公司计划推出2至3种主要产品来夺得25%市占率(1亿令吉)。

行家建议:

我们预计,联合药业可赢得新的EPO合约、及更新胰岛素合约,并保住市场领导地位。

我国的EPO市场市值达5000万令吉至6000万令吉间,相信该公司有能力与其他供应商竞争,争夺政府大约介于1000万令吉至1500万令吉的合约。

针对今年到期的胰岛素合约,相信该公司可凭借更便宜的价格,延长现有合约2年;若失败,将冲击下财年盈利预测7%。
12/03/2019 1:26 PM
keyin Why no movement,boring
16/03/2019 12:16 PM
Manekineko Hahaha, healthcare counter is like that la... Slow but steady...
18/03/2019 12:32 PM
Dakewlest Moving up. Any TP, anyone?
21/03/2019 6:49 PM
keyin Tp3
21/03/2019 7:15 PM
kmwong8711 For me above 1.30 is good
21/03/2019 7:59 PM
k3nthiew go! go! go!
22/03/2019 9:05 AM
k3nthiew Getting contract soon?
22/03/2019 9:05 AM
Investeye TA Research - 22 Mar 2019 Valuation & Recommendation :
We maintain Buy on Duopharma with a higher TP of RM1.61/share (previously RM1.52/share) based on unchanged 20.0x CY19 PER. We continue to like Duopharma for its: i) strong market share in Malaysia, and ii) move into niche pharmaceuticals products.
22/03/2019 9:41 AM